PL3452017T3 - Trwała przeciwnowotworowa kompozycja farmaceutyczna zawierająca temozolomid i sposób wytwarzania kompozycji - Google Patents
Trwała przeciwnowotworowa kompozycja farmaceutyczna zawierająca temozolomid i sposób wytwarzania kompozycjiInfo
- Publication number
- PL3452017T3 PL3452017T3 PL17725373T PL17725373T PL3452017T3 PL 3452017 T3 PL3452017 T3 PL 3452017T3 PL 17725373 T PL17725373 T PL 17725373T PL 17725373 T PL17725373 T PL 17725373T PL 3452017 T3 PL3452017 T3 PL 3452017T3
- Authority
- PL
- Poland
- Prior art keywords
- temosolomide
- anticogenic
- permanent
- making
- pharmaceutical composition
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1600150 | 2016-05-02 | ||
| EA201640026 | 2016-05-02 | ||
| PCT/SE2017/050418 WO2017192088A1 (en) | 2016-05-02 | 2017-04-28 | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition |
| EP17725373.9A EP3452017B1 (en) | 2016-05-02 | 2017-04-28 | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3452017T3 true PL3452017T3 (pl) | 2020-08-10 |
Family
ID=60203568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17725373T PL3452017T3 (pl) | 2016-05-02 | 2017-04-28 | Trwała przeciwnowotworowa kompozycja farmaceutyczna zawierająca temozolomid i sposób wytwarzania kompozycji |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10806732B2 (pl) |
| EP (1) | EP3452017B1 (pl) |
| CN (2) | CN118766906A (pl) |
| AU (1) | AU2017261137B2 (pl) |
| BR (1) | BR112018072603B1 (pl) |
| CA (1) | CA3022174C (pl) |
| DK (1) | DK3452017T3 (pl) |
| ES (1) | ES2776900T3 (pl) |
| HU (1) | HUE049403T2 (pl) |
| MX (1) | MX381521B (pl) |
| PL (1) | PL3452017T3 (pl) |
| WO (1) | WO2017192088A1 (pl) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0307802B8 (pt) * | 2002-02-22 | 2021-05-25 | Merck Sharp & Dohme | formulação farmacêutica compreendendo temozolomida, processo para a produção da mesma, bem como artigo fabricado contendo pó liofilizado compreendendo temozolomida |
| EP1838307A1 (en) | 2004-12-02 | 2007-10-03 | Schering Corporation | Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| CN100588399C (zh) | 2005-09-01 | 2010-02-10 | 天津帝士力投资控股集团有限公司 | 一种注射用替莫唑胺冻干粉针剂及其制备方法 |
| WO2008116053A2 (en) * | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Fap-activated chemotherapeutic compounds, and methods of use thereof |
| WO2011036676A2 (en) * | 2009-09-23 | 2011-03-31 | Ashwini Nangia | Stable cocrystals of temozolomide |
| RU2442586C1 (ru) * | 2009-11-11 | 2012-02-20 | Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) | Гидрогелевый противоопухолевый препарат |
| WO2011077458A1 (en) | 2009-12-23 | 2011-06-30 | Sahaj Life Sciences Pvt. Ltd. | Formulations of temozolomide for parenteral administration |
| US20140088036A1 (en) * | 2010-09-30 | 2014-03-27 | Universite De Strasbourg | Polyphosphate and pyrophosphate derivative of saccharides |
| KR20140087846A (ko) * | 2012-12-31 | 2014-07-09 | 주식회사 삼양바이오팜 | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |
| CN104274412A (zh) * | 2013-07-01 | 2015-01-14 | 北京恒瑞康达医药科技发展有限公司 | 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂 |
| US20160199392A1 (en) * | 2015-01-13 | 2016-07-14 | Autotelic Llc | Method for individualized drug therapy |
| CN104721155B (zh) * | 2015-04-07 | 2017-09-29 | 齐鲁制药(海南)有限公司 | 一种替莫唑胺冻干粉制剂及其制备方法 |
-
2017
- 2017-04-28 PL PL17725373T patent/PL3452017T3/pl unknown
- 2017-04-28 MX MX2018013243A patent/MX381521B/es unknown
- 2017-04-28 HU HUE17725373A patent/HUE049403T2/hu unknown
- 2017-04-28 US US16/098,524 patent/US10806732B2/en active Active
- 2017-04-28 EP EP17725373.9A patent/EP3452017B1/en active Active
- 2017-04-28 AU AU2017261137A patent/AU2017261137B2/en active Active
- 2017-04-28 WO PCT/SE2017/050418 patent/WO2017192088A1/en not_active Ceased
- 2017-04-28 CN CN202410769053.3A patent/CN118766906A/zh active Pending
- 2017-04-28 CA CA3022174A patent/CA3022174C/en active Active
- 2017-04-28 DK DK17725373.9T patent/DK3452017T3/da active
- 2017-04-28 ES ES17725373T patent/ES2776900T3/es active Active
- 2017-04-28 BR BR112018072603-6A patent/BR112018072603B1/pt active IP Right Grant
- 2017-04-28 CN CN201710293531.8A patent/CN107334766A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018013243A (es) | 2019-07-10 |
| EP3452017B1 (en) | 2020-02-19 |
| DK3452017T3 (da) | 2020-04-06 |
| ES2776900T3 (es) | 2020-08-03 |
| US20190142824A1 (en) | 2019-05-16 |
| AU2017261137B2 (en) | 2022-10-27 |
| BR112018072603A2 (pt) | 2019-04-30 |
| CA3022174A1 (en) | 2017-11-09 |
| CN118766906A (zh) | 2024-10-15 |
| CN107334766A (zh) | 2017-11-10 |
| CA3022174C (en) | 2024-01-02 |
| US10806732B2 (en) | 2020-10-20 |
| WO2017192088A1 (en) | 2017-11-09 |
| EP3452017A1 (en) | 2019-03-13 |
| MX381521B (es) | 2025-03-12 |
| BR112018072603B1 (pt) | 2023-12-26 |
| AU2017261137A1 (en) | 2018-11-15 |
| HUE049403T2 (hu) | 2020-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| IL258931A (en) | Therapeutic compounds and methods | |
| KR102609396B9 (ko) | Ldha의 발현을 억제하기 위한 방법 및 조성물 | |
| EP3513809A4 (en) | MEDICAL COMPOSITION | |
| PL3443009T3 (pl) | Przeciwciała i kompozycje anty-tim-3 | |
| EP3493799A4 (en) | CANNABIS | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| IL250744A0 (en) | A method for preparing flavociclib and its pharmaceutical preparations | |
| EP3436083A4 (en) | NOVEL COMPOSITIONS AND METHOD | |
| EP3493798A4 (en) | CANNABIS | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| EP3454899C0 (en) | PHARMACEUTICAL COMPOSITION | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| EP3436467A4 (en) | INNOVATIVE COMPOSITIONS AND THERAPEUTIC PROCEDURES | |
| DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
| IL266132A (en) | Pharmacological formulations and methods for their preparation | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| EP3305802A4 (en) | NOVEL PEPTIDE AND COMPOSITION THEREOF | |
| IL313083A (en) | Terlipressin compositions and their methods of use | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| EP3417845A4 (en) | ALPHA FORMULATION COMPOSITION AND ALPHA YELLOW COMPOSITION | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| EP3524250A4 (en) | PHARMACEUTICAL COMPOSITION |